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The gastrointestinal (GI) tract serves as a portal of entry for many microbial agents, and thus a complex immune system has evolved along the GI tract to protect the host. Many natural and man-made chemicals contact the host through the GI tract, and little is known about how environmental agents affect intestinal immune responses. Developing methods to assess parameters of immunotoxicology of the GI tract poses a significant and important challenge (Kawabata et al., 1995) . 1 This work was presented in oral form at the 12th annual Mechanisms of Immunotoxicology Conference on September 12, 1997, in Morgantown, WV. Several approaches to studying the effects of environmental toxins on intestinal immune responses have been studied. One approach is to perform host resistance assays with microbes that invade or colonize the GI tract. This method has been used to study the effects of cyclophosphamide on intestinal clearance of Trichinella spiralis (Luebke et al, 1992) , Candida albicans (Samonis et al, 1996; van Wyk et al, 1995) , Mycobacterium paratuberculosis (Follett and Czuprynski, 1990) , and Pseudomonas aeruginosa (Kawamura et al, 1990) . These studies have demonstrated that microbial clearance can be used to assess immunotoxicity; however, resistance studies do not test the effects of toxins on the immune mechanisms that are important in protection. Furthermore, the specific intestinal immune responses that clear these pathogens have not been characterized in detail.
The effects of toxins on immune responses in the GI tract can also be studied by assessing immune function, particularly the intestinal IgA response. Karacic and Cowdery measured diminished IgA production by Peyer's patch (PP) cells in vitro following mitogen activation (Karacic and Cowdery, 1987) and treatment with cholera toxin (Karacic and Cowdery, 1988) in mice exposed to cyclophosphamide. Kawabata et al. (1992) described suppression of anti-cholera toxin IgA responses in mice following exposure to cyclosporine A. In addition, IgA production was found to be altered in mice exposed to vomitoxin (deoxynivalenol) (Pestka et al, 1990a (Pestka et al, ,b 1991 . Proliferation of PP (Karacic and Cowdery, 1987) or mesenteric lymph node lymphocytes (Luebke et al., 1992 (Luebke et al., , 1995 has also been used as a measure of intestinal immunity.
The effects of toxins on lymphocyte cell number and distribution in gut associated lymphoid tissue (GALT) is a third method to study immunotoxicity of the intestine. This method has been used to study animals exposed to cyclophosphamide (Cozon et al, 1991; Hirakata et al, 1995; Yoshioka et al, 1990; Luebke et al, 1992) or vomitoxin (Pestka et al., 1990a (Pestka et al., , 1991 . The effects of bacterial toxins on intraepithelial lymphocytes (IEL), the cells interdigitated between absorptive epithelial cells, have also been investigated. These include studies on cholera toxin (Elson et al, 1995; Penney et al, 1996) and staphylococcal enterotoxin (Siebrecht et al, 1993) . These studies have contributed to the concept that toxins can affect intestinal immune function and point to a need for a system to examine several features of immune function following intestinal exposure to toxins and antigens. An ideal system to perform immunotoxicologic assessment of the GALT would provide the means to study several parameters of intestinal immunity, including host resistance, immune function, and alterations in organization of lymphoid tissue.
Enteric infection with reovirus provides such a system to assess immunotoxicology of the GI immune system. Reovirus (respiratory enteric orphan virus) is a nonenveloped dsRNA containing virus that is ubiquitous in nature and infects many mammalian (Nibert et al, 1996) species including humans and mice (Tyler and Fields, 1990) . In normal immunocompetent adult mice, enteric reovirus infection produces a self-limited infection in which extensive virus dissemination from the GI tract is rare, and virus is cleared from the GI tract within 7-14 days postinfection Barkon et al, 1996) . Intestinal reovirus infection has also been used as a probe to study the events involved in the induction and expression of intestinal immunity. Enteric infection elicits humoral immunity characterized by the production of virus-specific intestinal IgA London et al, 1987; Major and Cuff, 1996) and serum IgG (Virgin et al, 1988; Major and Cuff, 1996) . Cell-mediated immune responses include the appearance of virus-specific precursor cytotoxic T-cells (pCTL) in the GALT and spleen following oral infection (London et al, 1987; Cuff et al, 1993) . In the present report, we have examined die effect of cyclophosphamide treatment on viral clearance, the intestinal and systemic reovirus-specific immune responses, and lymphocyte distribution in GALT to determine whether this approach might provide a useful system to study immunotoxicity of the GI tract.
MATERIALS AND METHODS
Mice. Female Balb/cByJ mice aged 8 to 10 weeks were obtained from the Jackson Laboratories (Bar Harbor, ME). Mice were allowed to acclimate for 1 week prior to use in experiments. Virus-infected mice were housed in a laminar flow hood in microisolator cages in a separate room with negative pressure.
Virus. Third passage reovirus serotype 1, strain Lang (Tl/L) was used to infect mice. Stocks of reovirus were purified from infected L929 fibroblasts by freon extraction followed by CsCl density centrifugation as previously described (Smith et al, 1969) . Titers of purified virus were determined by plaque assays (Cuff et al, 1990) . Mice were infected with 3 X 10 7 plaque forming units of reovirus given by gavage in a total volume of 50 fd in borate-buffered saline containing gelatin (London et al., 1987) . Reovirus is considered a Class II pathogen and safety precautions consistent with the use of a Class II pathogen were employed during these studies.
Cyclophosphamide.
Cyclophosphamide [2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate (CY) produced by ASTA Pharma AG (Bielfeld, Germany) and distributed by Adria Laboratories, Columbus, OH] was a generous gift from Dr. Wei Shien, West Virginia University. Prior to use, CY was dissolved in sterile water. Mice were infected at day 0 and treated with cyclophosphamide at days -2, -1,0, +1, and +2. The total doses tested were divided in five equal daily doses given either by the ip or po routes. On the day of infection, cyclophosphamide was administered in the morning, and reovirus was administered in the afternoon. Investigators using cyclophosphamide wore gloves and disposed of cyclophosphamidecontaminated materials as chemical waste.
Virus titen. The intestinal contents from each intestine were removed by squeezing the contents out of one end with a sterile forceps. Each intestine was placed in 2 ml of sterile phosphate-buffered saline, frozen and thawed three times, homogenized (Brinkman, Westbury, NY), and sonicated (Misonix Inc., Farmingdale, NY). Virus titers were determined by plaque assays as previously described (Major and Cuff, 1997) .
Serum collection and fragment cultures. Ten days after infection (8 days after the final dose of cyclophosphamide), mice were anesthetized with sodium methohexital (Brevital) and exsanguinated by cardiac puncture. Serum was separated from clotted blood samples and stored at -20°C for later analysis. Peyer's patch and lamina propria (LP) cultures were established using a modification of the method of Logan et al. (1991) . For PP cultures, PP from each mouse (typically 7-10 patches/mouse) were removed, pooled, and washed five times in a medium consisting of RPMI 1640 supplemented with 5% fetal bovine serum (FBS) and 5 /ig/ml gentamicin. The patches from each individual mouse were cultured collectively in a total of 2 ml/culture in 24-well plates for 5 days at 37°C in an atmosphere of 5% CO 2 without additional stimulation. Tissue culture medium (TCM) consisted of RPMI 1640 supplemented with 10% FBS, 2 raM L-glutamine, 5 X 10~5 M 2-mercaptoethanol, 5 jtg/ml gentamicin, 100 U/m] penicillin, and 0.1 mg/ml streptomycin. Culture supematants were collected, clarified by centrifugation, and assayed for antibody by EL1SA.
Lamina propria cultures were established by removing the PP from intestines, splitting the intestines longitudinally, and cutting the tissue into pieces 3-5 cm in length. Intestinal fragments were subjected to two 30-min incubations at 37°C with stirring in a solution of 1 mM EDTA in Ca 2+ , Mg 2+ -free Hanks' balanced salt solution (HBSS) to remove epithelial cells. The intestine from each mouse was cultured individually. Fragments were washed twice in TCM and cultured in a total volume of 5 ml/culture in 6-well plates without additional stimulation. Five days after culture, the supematants were harvested, clarified by centrifugation, and then either stored frozen at -20°C or assayed for antibody by ELISA.
EUSA.
Serum and culture fluids were assayed for virus-specific antibody as previously described (Major and Cuff, 1996) . Wells of 96-well immunosorbent plates (Coming Costar, Cambridge, MA) were coated overnight at 4°C with 2.5 X 10 9 particles/well of reovirus Tl/L in 50 jil of 0.1 M NaH 3 CO (pH 8.0). Plates were washed twice with 200 /xl/well of PBS supplemented with 0.5% Tween 20 (PBS-T) and blocked with 200 ^.I/well of 3% (w/v) fraction V bovine serum albumin (Sigma, St. Louis, MO) for 2 h at room temperature. One-hundred microliters of twofold serial dilutions of serum or culture supernatant was added to each well in duplicate and incubated overnight at 4°C. The next day plates were washed four times and reacted with 100 /xl/well of purified biotinylated goat antibody specific for mouse Ig (heavy and light chain specific) or mouse IgA (Southern Biotechnology, Birmingham, AL) at a final concentration of 1 fig/ml m PBS supplemented with 10% bovine calf serum. Plates were then incubated for 45 min at room temperature. Following six washes in PBS-T, 0.25 /ig of avidin-conjugated peroxidase (Sigma) was added to each well and incubated for 30 min at room temperature. After eight washes with PBS-T, 100 fjd of 2,2'-azino-bis-3-ethylbenz-thiazoline-6-sulfonic acid (ABTS; Sigma) was added to each well, and color development was allowed to occur for 10 to 15 min. The plates were then read on an ELISA reader at 405 nm. Results are expressed as the geometric mean antibody Uter and were determined to be the last serum dilution that yielded an optical density (OD) > 0.200. Titration curves of known positive samples were found to be linear from approximately 1.0 to 0.1 OD units.
Quantitation of total and reovirus-specific IgA in fragment culture supematants was determined by assaying supematants as described above. Standard curves were generated for each plate by coating some wells with 1 jig/ml of purified goat anti-mouse immunoglobulin (Ig) (heavy and light chain-specific; Southern Biotechnology). Purified mouse IgA (Southern Biotechnology) at concentrations ranging from 20 to 0.1 ng/ml was added to wells coated with Downloaded from https://academic.oup.com/toxsci/article-abstract/42/2/99/1685783 by guest on 31 January 2019 anti-Ig. Reovirus-specific antibody concentrations were determined by direct comparison of OD values obtained from samples to the standard curves.
Culture of virus-specific pCTL
Single cell suspensions of spleens were prepared by expressing spleens through nylon mesh (Tetko Inc., Briarcliff Manor, NY) and lysing red blood cells with Tris-buffered ammonium chloride (Mishell et ai, 1980) . Single cell suspensions were washed three times with RPM1 1640 containing 5% FBS and antibiotics and resuspended in TCM at 10 7 cells/ml. Cells were incubated with reovirus at a multiplicity of infection (M.O.I.) of 1 for 45 min at room temperature. Following incubation, cells were washed once and resuspended in TCM at a density of 4 X 10 s cells/ml. Cell cultures were incubated for 5 days at 37°C in an atmosphere of 5% CO 2 . Following incubation, cells were harvested and live lymphocytes were enriched on Ficoll-Hypaque density gradients and used in cytotoxicity assays.
Cytotoxicity assays. Lymphocytes were incubated in a 4-h 5 ' Cr release assay at various effector-target ratios with 5000 "Cr-labeled noninfected or reovirusinfected KD2SV target cells in a final volume of 200 iU of TCM. Virus-infected target cells were prepared by incubating KD2SV cells overnight at 31°C with reovirus at a M.O.I, of 10. Cells were 51 Cr labeled for 1 h at 37°C with 100 iiCi of sodium dichromate 51 Cr (New England Nuclear, Topsham, MA) prior to use. Following the 4-h incubation, 100 /xl of medium was removed from each well and released radioactivity was counted with a gamma counter. Specific lysis was calculated using standard methods (Grabstein et aL, 1980) .
Flow cytometry.
Single cell suspensions of PP lymphocytes were isolated by dissecting PP from the small intestine (SI) and mechanically disassociating lymphocytes from the tissue using 18-gauge needles. Single cell suspensions were passed over nylon wool columns to remove tissue debris and recovered cells were washed three times in wash medium and counted. Intraepithelial lymphocytes were isolated by a modification of published methods (Mosley and Klein, 1992) . Small intestines were split longitudinally and cut into pieces 3-5 cm in length. Intestinal contents were removed by shaking the pieces in three successive rinses of Ca 2+ , Mg 2+ -free HBSS supplemented with 10 mM Hepes Fragments were then cut into pieces of approximately 1 cm in length. Intestinal fragments from one to three mice were suspended in 40 ml of a solution of 1 mM EDTA and 1 mM dithiothreitol dissolved in Ca 2+ , Mg 2+ -free HBSS supplemented with 10 mM Hepes. The intestinal fragments were incubated in two successive washes for 30 min each at 37°C with stirring in sterile 100-ml bottles. Fragments were rinsed two to three times with sterile HBSS, and the eluted cells from both washes were pooled and passed over a column of nylon wool to remove epithelial cells and debris. Columns were made with 0.015 g of nylon wool packed lightly into sterile disposable 10-mI syringes. Lymphocytes that passed through the column were separated from intestinal epithelial cells by percoll gradients. Cells from 1-3 intestines were suspended in 5 ml of 42% percoll (Sigma) diluted in HBSS and overlaid onto layers of 2 ml of 70% percoll in 15-ml centrifuge tubes. Gradients were overlaid with 1 ml of HBSS and centnfuged at 600g for 20 min. Enriched IEL were removed from the 42-70% interface. Yields from normal mice ranged from 2 to 5 X 10 6 lymphocytes per mouse.
Lymphocytes were stained with appropriate dilutions of fiuorochromeconjugated antibodies. For staining PP lymphocytes, 5 X 10 5 cells were suspended in a final volume of 25 /xl of fluorescein-conjugated anti-CD4, anti-CD8, or anti-B220 (Caltag Laboratories, San Francisco, CA) diluted in PBS supplemented with 1 % bovine calf serum and 0.04% sodium azide (FACS medium) and incubated in the dark on ice for 30 min. Following incubation, cells were washed an additional two tintcs in FACS medium, fixed in 0.4% paraformaldehyde in PBS, and analyzed on a FACScan (Becton-Dickinson, San Jose, CA). IEL were stained using a double staining method. One million cells were suspended in a final volume of 25 /xl of appropriately diluted fluorescein-conjugated anti-CD8 and phycoerythrin-conjugated anti-CD4 (PharMingen, San Diego, CA) or fluorescein-conjugated anti-a/0 T-cell receptor (TCR) and phycoerythrin-conjugated anti--y/5 TCR (PharMingen). Additional samples of IEL were stained using a two-step method. In the first step, IEL were incubated in a mixture of fluorescein-conjugated anti-CD8a and biotinylated anti-CD8/3 (PharMingen) for 30 mm on ice in the dark. (0); oral CY at 100, 300, or 500 mg/kg; or intraperitoneal CY at 200 mg/kg over a 5-day period. On day 3, mice were infected with 3 X 10 7 PFU of reovirus by the oral route. Ten days after infection virus titers in small intestines were determined by plaque assay. Each point represents analysis of an individual mouse. Asterisks denote statistically significant differences from the vehicle control by Kruskal-Wallis test and Dunn's test. Data are combined from two separate experiments. conjugated avidin. Cells were incubated for an additional 30 min as described above. Following the second incubation, stained IEL were washed twice in FACS medium and analyzed as described above. Epithelial cells were gated out of the analysis based on forward and side light scatter.
Data analysis. Data were tested by one-or two-way analysis of variance. When significant differences were found among groups, the data from experimental and control groups were compared using Dunnett's or Bonferroni's test. Data not normally distributed were compared using the Kruskal-Wallis test followed by Dunn's test to compare experimental to control data. Statistical analyses of immunoglobulin concentrations in fragment culture supernatants were performed using analysis of variance followed by orthogonal contrast analysis to identify statistically significant trends.
RESULTS

Intestinal Virus Titers in CY-Treated Mice
Intestinal reovirus inoculation in immunocompetent mice produces a self-limiting, subclinical infection. We first determined whether CY exposure affected the ability of treated mice to clear virus as a measure of the effect of CY on host resistance. Mice were treated with various doses of CY po or 200 mg/kg ip for 5 days and orally infected with reovirus on day 3 of CY treatment. Ten days after infection, virus titers were determined in intestines and spleens. Mice that received vehicle alone effectively cleared virus from the gut by day 10 after infection. There was a dose-dependent increase in the number of CY-treated mice that had detectable virus in their intestines 10 days after infection (Fig. 1) . Statistically significant differences in virus titers in intestines were detected in mice given either 500 mg/kg po or 200 mg/kg ip compared to the vehicle control. No replicating virus was found in the spleens of any of the treated animals (data not shown).
Immune Responses to Intestinal Reovirus Infection in CY-Treated Mice
It is well established that CY treatment reduces systemic antibody responses in infected animals. Enteric reovirus infection induces intestinal and systemic virus-specific antibody responses, and we determined whether CY treatment affected the systemic and intestinal antibody responses following oral infection. Ten days after infection, a dose-dependent inhibition of the virus-specific serum antibody response was observed in mice given CY (Fig. 2) . Serum antibody responses were greatly diminished in mice given 500 mg/kg po and barely detectable in mice given CY ip. Statistically significant differences in serum antibody titers were found in mice given 300 or 500 mg/kg po or 200 mg/kg ip.
Antibody concentrations in PP and LP cultures from reovirus-infected CY-treated mice were also assessed (Table 1) . No statistically significant differences in the total IgA output were observed in the CY-treated groups compared to control cultures. Virus-specific responses in PP were undetectable in mice treated with 200 mg/kg ip and detectable in only one of four mice given 500 mg/kg orally. Orthogonal contrast analysis of the immunoglobulin concentrations in these culture supernatants revealed a statistically significant difference in virusspecific antibody in cultures from mice given either 500 mg/kg po or 200 mg/kg ip CY compared to control cultures from mice that received vehicle alone or cultures from mice that were treated with 100 or 300 mg/kg po (p < 0.02). Similar responses were observed in LP fragment culture supernatants. The high dose of oral CY or CY given ip reduced the virus-specific IgA responses (p < 0.001), but not the total IgA response.
Reovirus-Specific Cytotoxic T-Cell Responses in CY-Treated Mice
Enteric reovirus infection induces pCTL that express virusspecific cytotoxicity in in vitro 51 Cr release assays following in vitro stimulation with reovirus-pulsed antigen-presenting cells. This feature of the cellular immune response is commonly observed in response to nonmajor histocompatibility complexencoded antigens such as viruses or minor alloantigens (Wunderlich et ai, 1997) . Mice were given either saline or CY for 5 days at total doses of 100, 300, or 500 mg/kg orally. Ten days after infection, spleen cells were stimulated in vitro with reovirus for 5 days and the virus-specific CTL responses were determined by 51 Cr release assays. Virus-specific killing was assessed by comparing specific cytotoxicity of spleen cells against virus-infected or noninfected targets. Substantial virusspecific CTL activity was expressed by lymphocytes from mice given vehicle or 100 mg/kg CY and restimulated with virus in vitro for 5 days. Lymphocytes from mice given 300 or 500 mg/kg had virtually undetectable responses (Fig. 3) . (7133) " Values represent the IgA concentrations (ng/ml ± SE) in supematants from individual cultures of tissues from four mice. Data are from one of two separate experiments with similar results.
* Supernatants from three of four mice tested had detectable specific antibody.
c Supematants from one of four mice tested had detectable antibody. d Significantly different from 0, 100, or 300 mg/kg by ANOVA and orthogonal contrast analysis (p < 0.001).
' Significantly different from 0, 100, or 300 mg/kg by ANOVA and orthogonal contrast analysis (p < 0.02). 
Effects of CY and Reovirus on Gut-Associated Lymphoid Tissue
Cyclophosphamide treatment induced a generalized lymphopenia in nonsplenic secondary lymphoid tissue. The effect of oral reovirus infection on lymphocyte numbers and phenotype in CY-treated mice was assessed to determine whether oral reovirus infection altered the effects of CY. As previously reported by others (Cozon et ai, 1991) , we found that PP were hypocellular in CY-treated mice. Peyer's patch numbers were decreased 3-to 19-fold in CY-treated mice, regardless of whether they were infected with reovirus ( Table 2 ). The percentage of B-cells in PP was reduced and the percentage of CD4+ T-cells was increased in CY-treated mice compared to controls (Table 3) . When mice were treated with CY, the percentage of B220+ cells dropped from 57-68% to 35-37%, and the percentage of CD4+ cells increased from 19-24% to 37-41% (p < 0.05). However, reovirus infection did not affect the distribution of B-and T-cells in CY-treated mice as determined by two-way ANOVA.
Flow Cytotnetric Analysis of IEL from CY-Treated Mice
There is little information on the effects of CY treatment on IEL populations in the gut. The role of these cells in resistance to infection, especially virus infection, is also unclear, but it has been suggested that EEL play a role in regulating cellular and humoral intestinal immune responses and in mediating cellular immune responses against intracellular pathogens that invade through the intestine. The phenotypes of IEL from mice treated with 500 mg/kg CY for 5 days were examined 2 and 5 days after the final dose of CY. The IEL appeared normal by flow cytometry (Fig. 4) , although the numbers of IEL were reduced approximately five-fold in two separate groups of mice (data not shown). That is, IEL from CY-treated mice were predominantly CD8+ (approximately 75%). Some EEL expressed the CD8aa homodimer and some cells expressed the CD8a/3 heterodimer (47 and 28%, respectively). Both a//3 and •y/8 T-cell receptors expressing EEL were found in similar proportions in control and CY-treated mice. The epithelium also contains a population of CD4+CD8+ T cells. These were also found in similar percentages in control and CY-treated mice (11 and 9%, respectively). 
DISCUSSION
This study was undertaken to determine whether enteric reovirus infection was a suitable model to assess the effects of chemical exposure of the GI tract on the generation and expression of intestinal immunity. Using enteric reovirus infection it is possible to assess many parameters of the "Tier 2" level of immunotoxicology testing as described by Luster et al. (1988) including measurements of specific humoral and cellular immunity as well as host resistance. We examined the response to infection in CY-treated mice because the immunotoxicity of CY is well documented. It is active following oral exposure (Moore, 1991) , and it has been used to validate methods of immunotoxicity testing (Luster et al., 1988) .
Reovirus infection in adult immunocompetent mice produces a serf-limiting infection of the gut with little dissemination of virus to the periphery (Rubin et al., , 1986 Barkon et al., 1996; Major and Cuff, 1996) . Elimination of virus from the gut is likely due to contributions by specific local humoral and cellular immune responses since infections in severe combined immunodeficient mice are lethal (George et al., 1990) . Therefore chemical-induced alterations of intestinal immunity could affect viral clearance. Cyclophosphamide treatment inhibited viral clearance in a dose-dependent manner and CY at doses of either 500 mg/kg po or 200 mg/kg ip were equally effective. Intermediate doses of CY resulted in some individual mice clearing virus while others had not. Interestingly, virus did not disseminate from the gut to the spleen even in immunosuppressed mice, reinforcing the notion that assessment of host resistance in the intestine is an important aspect of studying intestinal immunotoxicity. In contrast to other model pathogens that have been proposed for use in Tier 2 assays, such as Listeria monocytogenes, Streptococcus pneumoniae, influenza virus, and Plasmodium yoelii (Luster et al., 1988) , reovirus replicates and spreads through the intestine following oral infection of immunocompetent mice, and presumably intestinal immune responses have evolved to combat agents that naturally infect the gut. By using an agent that naturally infects the gut and is controlled by the intestinal immune response, we are able to assess the effects of toxins on immune responses that are central to the health of the host. We conclude that reovirus could serve as a useful pathogen to study host resistance in the intestine and periphery following exposure to a wide range of potentially immunotoxic agents.
We measured the systemic and local humoral immune responses to enteric reovirus infection in CY-treated mice. A single dose of replicating virus induces a serum IgG response (Major and Cuff, 1996) . The 500 mg/kg oral dose of CY suppressed the response to levels approaching that found when mice were given 200 mg/kg ip. It is well documented that CY treatment inhibits the induction of serum antibody to infectious agents (Kishimoto et al., 1990; Amarante-Mendes et al., 1991; Cozon et al., 1991; Blejer et al., 1995) , and this finding again demonstrates the utility of using intestinal reovirus infection as a model to study systemic and intestinal immunotoxicity. Although the source of initiation of the serum antibody response had not been established, the mesenteric lymph node is a possible site because virus-specific IgG can be found in cultures of mesenteric lymph nodes from infected mice (Major and Cuff, 1996) . It is likely that the depressed antibody response was due to CY-mediated elimination of reovirus-activated B-cells in the mesenteric lymph nodes and spleens from treated mice. The results suggest that CY inhibits both systemic and mucosal immune responses after oral CY treatment. This conclusion is supported by the fact that CY is readily absorbed through the gut and biotransformed to active metabolites by the liver (Moore, 1991) .
Although measurement of serum antibody levels is informative about the systemic immune response to infection, we were most interested in determining whether we could assess intestinal antibody responses in a manner that was quantitative. We also wanted to process tissues from individual mice to perform dose-response studies and apply statistical analyses to the data. We found that increased viral load, as measured by virus tissue titers, corresponded to decreased levels of virus-specific serum IgG and decreased levels of virus-specific intestinal IgA. Decreased intestinal IgA responses were observed in both the PP, the inductive site of the intestinal anti-reovirus response, and the LP, the effector site of the intestinal immune response. Longer-term studies have not yet been performed to determine whether intestinal immune responses ultimately recover and virus is cleared in CY-treated mice or whether some type of immunologic nonresponsiveness develops in the gut. Those questions could be significant to understanding immunologic recovery in humans treated with CY.
These results extend the approaches used by others to assess IgA production during treatment with immunomodulating drugs. Kawabata et al. (1992) showed that cholera toxinspecific IgA in intestinal secretions from cyclosporine-treated mice could be measured semiquantitatively by ELISA. The same group quantitated antibody-forming cells in LP by enzyme-linked immunospot assays (ELISPOT). The ELISPOT assay on LP cells is quantitative, but this method is technically challenging and too cumbersome to test individual animals in large experiments. The fragment culture system described by Logan et al. (1991) is technically easier to perform and enables investigators to analyze responses by individual animals in multiple dose experiments. Furthermore, fragment cultures can be used to study in vitro effects of toxins on GALT. This feature could be useful in elucidating mechanisms of immunotoxicity in the GI tract. However, it should be noted that the fragment cultures require in vitro incubation which lengthens the experimental protocol and adds an additional potential source of variation. An alternative method not used in this study is the measurement of coproantibodies. This approach has the advantage of being noninvasive, and it makes it possible to sample multiple time points from the same animal.
The total IgA response was not significantly different among groups 8 days after the final dose of CY. However, there was variation in total IgA output among and within groups. This is likely due to biologic variations between individual animals and the recovery of IgA responses following CY treatments. Cozon et al. (1991) reported that IgA production was initially inhibited and then increased to normal levels in intestinal secretions between 8 and 12 days after CY exposure. Because we were interested in reovirus-specific antibody, we did not test animals at shorter intervals after CY treatment. We suspect that total IgA was probably transiently suppressed in CYtreated animals as previously reported. Our results, and the results of Kawabata et al. (1992) , indicate that measurements of antigen-specific responses in the gut are more sensitive indicators of immunotoxicity than measurements of total IgA, particularly at later time points after exposure.
We also examined cytotoxic cell responses to virus infection in CY-treated mice. B-cells are more sensitive to CY than T-cells (Turk and Parker, 1982) . However, when CY is given after antigen exposure, T-cell responses are also inhibited, presumably due to elimination of antigen-activated proliferating T-cells (Eto et al., 1990a,b; Sulikowska and Lewicki, 1990) . In some studies low doses of CY enhanced T-cellmediated immunity (Lagrange et al, 1974; Ascher et al, 1977) , but the mechanisms for this phenomenon remain to be completely elucidated. Doses of 300 or 500 mg/kg inhibited the induction of virus-specific pCTL following infection.
Reovirus-specific CTL activity is mediated by CD8+ Tcells (London et al, 1987) . Flow cytometric analysis of spleen cells that were stained prior to culture indicated that there was a twofold higher frequency of CD8+ T-cells in spleens from CY-treated mice compared to nontreated mice (data not shown). Therefore, the lack of CTL-mediated killing was not due to a generalized loss of CD8+ T-cells, but likely due to selective killing of reovirus-activated CD8+ T-cells by CY. These experiments again demonstrate the advantage of reovirus infection as a probe to study immunotoxicity compared to protein antigens such as cholera toxin which do not elicit CTL responses following oral exposure. Similar studies could be performed to assess CTL responses directly from either PP or IEL since reovirus induces pCTL in the gut following enteric infection (London et al, 1987; Cuff et al, 1993) . We found that suspensions of PP cells from CY-treated mice did not survive during in vitro culture. This is likely due to the substantial cytotoxicity of CY. Whether a similar technical difficulty will be observed following testing with less cytotoxic agents remains to be determined.
We asked the question whether reovirus infection hastened the recovery of intestinal immune responses, perhaps by providing an additional stimulus for production or recruitment of B-cells to the gut. However, there was no statistically significant increase in the number of lymphocytes in PP from CYtreated reovirus-infected mice compared to noninfected mice. It is possible that such an effect might be apparent later in infection if CY-treated mice ultimately mount an antibody response to reovirus.
The effect of CY treatment on intraepithelial cell phenotype was found to be minimal, although CY treatment reduced the number of cells isolated from treated mice. PEL are a poorly understood population of cells that are composed of several subpopulations not typically found in the periphery (GuyGrand and Vassilli, 1993) . The intestine has been suggested to be a site of extrathymic differentiation, so we thought it possible that CY treatment could specifically affect distinct subpopulations of cells differentially if some populations were proliferating. Our data suggest that none of the populations were differentially susceptible to CY, and thus none are likely proliferating at high levels. This result is in agreement with other studies assessing rates of proliferation by IEL (Penny et al, 1995) . It should be noted that 2 and 5 days after treatment the number of IEL recovered per mouse was approximately fivefold lower than in vehicle-treated mice (data not shown). It is not clear whether the loss if IEL was a direct effect or secondary to possible effects of CY on intestinal epithelial cell integrity. An alternative explanation includes the possibility that CY affected an IEL precursor that differentiated into distinct populations, but the lineage of all of the populations of IEL is not yet resolved. While quantitative analysis of IEL from treated mice does not easily lend itself to studies of drug toxicity, the experiments yielded information about IEL in CY-treated mice. Nonetheless, we demonstrate that IEL can be assessed with a Tier 2 assay of immunotoxicity.
In conclusion, we have demonstrated that enteric reovirus infection of the gut can be used to assess specific immune responses of the intestine and periphery following exposure to potentially immunotoxic compounds. This system can be used to perform quantitative analyses on individual mice, yielding data that can be analyzed using appropriate statistical methods. Virus-specific humoral and cellular immune responses can be measured using this system.
